The New Array of Choices in Prostate Cancer—What’s Best for Your Patients? Part 2
PCE
English - February 10, 2022 19:15 - 30 minutes - 28.2 MB - ★★★★ - 6 ratingsCourses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this second of two podcasts, Rana R. McKay, MD, and Arjun Balar, MD, and moderator Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN, discuss the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-resistant or castration-sensitive prostate cancers, including the use of taxanes, androgen receptor agonists, and other therapies.
This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributor:
Arjun Balar, MD
Rana R. McKay, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
Ms Sims: consulting fees: Coloplast.